CSL Behring receives FDA approval of RiaSTAP CSL Behring announced today that the U.S stendra cost . Food and Medication Administration offers granted marketing approval for RiaSTAP, the only and first treatment of severe bleeding episodes in sufferers with congenital fibrinogen insufficiency, including afibrinogenemia and hypofibrinogenemia. Congenital fibrinogen insufficiency is a rare, possibly life-threatening bleeding disorder that impacts an estimated one person per million, with an estimated prevalence in the U.S. Of approximately 300 patients. RiaSTAP is not indicated to treat dysfibrinogenemia. RiaSTAP was granted orphan status in March 2008 and priority review in August 2008.
The most common form of VTE is normally deep vein thrombosis , which often occurs in the ‘deep veins’ in the hip and legs or pelvis. An embolism is created if the clot travels through the venous system. Bloodstream clots lodging in the lungs are known as a pulmonary embolism . Estimates claim that at least 350,000 and as much as 600,000 Americans contract DVT/PE annually, and at least 100,000 deaths are thought to be related to these illnesses each full year. Additional results of this secondary endpoint analysis of JUPITER demonstrated rosuvastatin 20mg produced a substantial 55 percent reduction in the chance of DVT and a non-significant 23 percent decrease in PE .